Full Press Release Details
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome.
RARE
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
Key Takeaway: Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
Price reaction · baseline $37.12 (2025-06-26 close) · hit after-hours · clean, no other RARE news in the window
day 0 close · peak
-1.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia